Elevate Capital Advisors LLC Has $2.61 Million Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Elevate Capital Advisors LLC increased its stake in Eli Lilly by 273.6% in Q4 to 2,432 shares valued at $2.613 million, making LLY about 1.7% of its portfolio and its 22nd largest holding.
• Analysts hold a generally positive view with a consensus rating of "Moderate Buy" and an average price target of $1,224.59, reflecting 2 Strong Buy, 23 Buy, 4 Hold and 1 Sell ratings.
• Eli Lilly beat quarterly estimates (EPS $7.54 vs. $7.48; revenue $19.29B vs. $17.85B), posted revenue up 42.6% YoY, set FY2026 EPS guidance of 33.50–35.00, and has recent pipeline and strategic wins (Foundayo approval, positive Jaypirca Phase 3, CrossBridge acquisition) supporting growth momentum.

Elevate Capital Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 273.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,432 shares of the company's stock after purchasing an additional 1,781 shares during the quarter. Eli Lilly and Company accounts for approximately 1.7% of Elevate Capital Advisors LLC's investment portfolio, making the stock its 22nd biggest position. Elevate Capital Advisors LLC's holdings in Eli Lilly and Company were worth $2,613,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of LLY. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company's stock worth $61,771,785,000 after buying an additional 551,659 shares during the last quarter. State Street Corp grew its stake in shares of Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company's stock worth $26,496,364,000 after buying an additional 219,590 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company's stock worth $11,112,164,000 after buying an additional 574,229 shares during the last quarter. Finally, Capital International Investors grew its stake in shares of Eli Lilly and Company by 6.1% during the third quarter. Capital International Investors now owns 10,001,509 shares of the company's stock worth $7,628,447,000 after buying an additional 579,381 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. HSBC cut shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and decreased their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. The Goldman Sachs Group set a $1,260.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Finally, TD Cowen boosted their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,224.59.

Eli Lilly and Company Price Performance

LLY stock opened at $922.83 on Wednesday. The firm has a market cap of $871.91 billion, a price-to-earnings ratio of 40.21, a PEG ratio of 1.08 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company's fifty day simple moving average is $980.12 and its 200 day simple moving average is $980.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jaypirca (pirtobrutinib) posted positive Phase 3 BRUIN CLL‑322 results showing significantly extended progression‑free survival when added to venetoclax + rituximab — a fourth positive Phase 3 readout that meaningfully strengthens Lilly’s oncology franchise and potential label expansion. PR Newswire: Jaypirca Phase 3
• Positive Sentiment: Lilly acquired preclinical ADC specialist CrossBridge in a roughly $300M deal, adding antibody‑drug conjugate expertise to its oncology pipeline — an inorganic move that accelerates biologics/ADC capabilities. FierceBiotech: CrossBridge acquisition
• Positive Sentiment: Lilly expanded external AI ties by enabling Vasa Therapeutics to use Lilly’s TuneLab AI/ML drug‑discovery models — this monetizes Lilly’s platform and can accelerate external partnerships and milestone revenue. Yahoo Finance: Vasa / TuneLab
• Positive Sentiment: Regulatory approval of Foundayo (Lilly’s oral GLP‑1 weight‑loss pill) continues to underpin the company’s blockbuster growth narrative and long‑term revenue trajectory in obesity care. The Motley Fool: Foundayo approval
• Neutral Sentiment: Media speculation about a long‑term bull case (e.g., a Forbes piece arguing LLY could reach $2,000) boosts narrative optimism but is highly model‑dependent and not new fundamental news. Forbes: LLY $2,000 thesis
• Neutral Sentiment: Analyst price‑target activity is mixed — outlets show fresh raises (to $880 and to $1,327), highlighting divergent views on near‑term valuation vs. long‑term growth. Investors should note wide target dispersion. American Banking News: PT $880 American Banking News: PT $1,327
• Negative Sentiment: Competitive risk: Novo Nordisk’s new partnership with OpenAI to speed drug development underscores intensifying AI‑driven competition in the obesity/GLP‑1 space, which could pressure market share and future growth assumptions for Lilly. Pharmaceutical-Technology: Novo + OpenAI

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.